Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent.~* Participant is aged ≥ 60 days to ≤ 75 days.~* Participant without preventive inoculation of polio vaccine and previous history of Polio.~* Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.~* Body temperature ≤ 37.5℃.~Exclusion Criteria:~* Known allergy to any constituent of the vaccine.~* Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever.~* Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth.~* Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction.~* Known bleeding disorder.~* Receipt of the whole blood, blood plasma or immunoglobulin before the trial vaccination.~* Reported the history of acute illness had need systemic antibiotics or antiviral treatment of infections in the 7 days preceding the trial vaccination.~* An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding enrollment in the trial.~* Participation in any other intervention clinical trial.~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine.

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 75 Days
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
- Group 2 (Type: EXPERIMENTAL): The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
- Group 3 (Type: EXPERIMENTAL): The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.

Based on this trial design, predict the completion outcome and termination type (if applicable).